AzTrials
AzTrials

Anatomic Stage I Breast Cancer AJCC v8NCT07259304

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

An observational study of Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IA Breast Cancer AJCC v8, run by University of Southern California at 3 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer… Read more about this study

Who is it for?
Ages 18 to 39 years
What is being tested?
Medical Device Usage and Evaluation, Quality-of-Life Assessment and Survey Administration
How many people
173 participants
Where
3 sitesUnited States
Study dates
24 Nov 2021to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 39 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.

Who may be able to join

  • Age 18-39 years at cancer diagnosis.
  • Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
  • Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
  • Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
  • Clinician assessed expected survival greater than 12 months at time of diagnosis.
  • Able to complete questionnaires and wear a wrist worn accelerometer.
  • English or Spanish speaking.

Who cannot join

  • Leukemia (excluded due to longer treatment duration and different care trajectory).
  • Primary language other than English or Spanish.
  • Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.

Trial locations and contacts

3 sites in 1 country.

United States3 sites
  • MD Anderson Cancer Center

    Houston, Texas, 77030

  • Los Angeles General Medical Center

    Los Angeles, California, 90033

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033

Other trials in United States

About this study

Official title: Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study

This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.

Read the detailed description

PRIMARY OBJECTIVES:

  1. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.

OUTLINE:

Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Being tested
Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
Medical subject headings
Central Nervous System Neoplasms, Hodgkin Disease, Bone Neoplasms, Brain Neoplasms, Testicular Neoplasms, Lymphoma, Non-Hodgkin, Uterine Cervical Neoplasms, Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Medical Device Usage and EvaluationOther

    Wear an actigraph GT3X-BT accelerometer

  • Quality-of-Life AssessmentOther

    Also called Quality of Life Assessment

    Complete survey

  • Survey AdministrationOther

    Complete survey

Study groups in NCT07259304
Study groupRoleWhat they receive
Observational (actigraph, surveys)Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
Receives: Other: Medical Device Usage and Evaluation; Other: Quality-of-Life Assessment; Other: Survey Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in social role functioning

    Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation).

    Measured: Baseline up to 1 year

  2. Change in perceived emotional support

    Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support).

    Measured: Baseline up to 1 year

  3. Change in perceived informational support

    Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support).

    Measured: Baseline up to 1 year

  4. Change in perceived instrumental support

    Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support).

    Measured: Baseline up to 1 year

  5. Change in loneliness score

    Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness).

    Measured: Baseline up to 1 year

  6. Change in social anxiety symptoms

    Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety).

    Measured: Baseline up to 1 year

  7. Change in social network density

    Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network).

    Measured: Baseline up to 1 year

  8. Change in proportion of supportive social ties

    Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network).

    Measured: Baseline up to 1 year

  9. Change in frequency of social contact

    Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact).

    Measured: Baseline up to 1 year

  10. Change in total daily physical activity

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity).

    Measured: Baseline up to 1 year

  11. Change in total daily sedentary time

    Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time).

    Measured: Baseline up to 1 year

Secondary outcomes (2)
  1. Change in Quality of Life

    Patient reported quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10, assessed at baseline and 12 month follow up. This is a 10-item patient-reported questionnaire measuring general physical, mental, and social health. Most questions use a 1-to-5 point scale. Higher numerical values consistently represent better health or lower symptoms. The survey produces two separate scores: Global Physical Health (GPH) and Global Mental Health (GMH). Raw response values are summed and converted into standardized T-scores where a score of 50 represents the U.S. general population average (standard deviation of 10).

    Measured: Baseline up to 1 year

  2. Symptom Burden

    Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints. This survey is a multi-symptom patient-reported outcome (PRO) measure used to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms.

    Measured: Baseline up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2025
  2. Study start24 Nov 2021
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
173 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07259304
Sponsor's protocol ID
0S-20-10
Other IDs
NCI-2021-05723, 0S-20-10, P30CA014089, R37CA256867
Status last verified
Oct 2026
First submitted
14 Oct 2021
Last updated
5 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IA Breast Cancer AJCC v8, run by University of Southern California at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in social role functioning (time frame: Baseline up to 1 year). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in